期刊文献+

厄洛替尼对大鼠小肠上皮细胞跨膜转运的影响

Effects of Erlotinibon the Transmembrane Transport of Intestinal Epithelial Cells in Rats
下载PDF
导出
摘要 目的:分析厄洛替尼对大鼠小肠上皮细胞跨膜转运的影响。方法:通过在体肠灌流及大鼠药动学实验,比较厄洛替尼给药组与对照组药动学参数的变化。结果:多次给予厄洛替尼后,大鼠的体重及摄食量显著下降,荧光素钠的小肠透过率增加,单次给予厄洛替尼有增加头孢克洛吸收的趋势。结论:厄洛替尼可通过增加细胞旁路通透性从而增加小肠上皮的吸收。 Objective: To study the effect of erotinib on transmembrane transport of intestinal epithelial cells in rats. Methods: The changes of pharmacokinetic parameters in erlotinib group and control group were compared by intestinal perfusion and pharmacokinetic experiments in rats. Results: After repeated erlotinib administration, the weight and food intake of the rats decreased significantly, and the intestinal transmittance of luciferin sodium increased. Single administration of erlotinib tends to increase cefaclor absorption. Conclusion: Erotinib can increase intestinal epithelial absorption by increasing paracellular permeability.
作者 刘治芳 朱艳妮 Liu Zhi-fang;Zhu Yan-Ni(Changsha Medical University, Changsha 410219)
机构地区 长沙医学院
出处 《生物化工》 2019年第5期27-29,共3页 Biological Chemical Engineering
基金 湖南省教育厅科研项目(项目编号:15C0160)
关键词 厄洛替尼 膜通透性 吸收 Erlotinib Membrane permeability Absorption
  • 相关文献

参考文献1

二级参考文献10

  • 1Salomon DS,Brandt R,Ciardiello F,et al.Epidermal growth factor-related peptides and their receptors in human malignancies[J].Crit Rev Oncol Hematot,1995,19:183-232.
  • 2Fontanini G,De Laurentiis M,Vignati S,et al.Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage Ⅰ-Ⅲ A non-small cell lung cancer:amphiregulin and microvessel count are independent prognostic indicators of survival[f].Clin Cancer Res,1998,4:241-249.
  • 3Grunwald V,Hidalgo M.Developing inhibitors of the epidermal growth factor receptor for cancer treatment[J].J Natl Cancer Inst,2003,95:851-867.
  • 4Shepherd FA,Rodrigues J,Ciuleanu T,et al.Erlotinib in previously treated non-small cell lung cancer[J].N Engl J Med,2005,353:123-132.
  • 5Bezjak A,Shepherd F,Tu D,et al.Symptone response in non-small cell lung cancer (NSCLC) patients treated with erlotinib:quality of life analysis of the NCIC CTG BR.21 trial[C].ASCO,2005.
  • 6Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL Trial)[J].J Clin Oncol,2003,21:2237-2246.
  • 7Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA,2003,290:2149-2158.
  • 8Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib[J].N Engl J Med,2004.350(21):2129-2139.
  • 9Tsao MS,Sakurada A,Cutz JC,et al.Erlotinib in lung cancer-molecular and clinical predictors of outcome[J].N Engl J Med,2005,353:133-144.
  • 10Sridhar SS,Seymour L,Shepherd FA.Inhibitors of epidermal-growth-factor receptors:a review of clinical research with a focus on non-small cell lung cancer[J].Lancet Oncol,2003,4:397-406.

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部